| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.
|
Biol Blood Marrow Transplant
|
2005
|
19.83
|
|
2
|
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.
|
Blood
|
2004
|
3.61
|
|
3
|
Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
|
Blood
|
2009
|
2.73
|
|
4
|
HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry.
|
N Engl J Med
|
2014
|
2.69
|
|
5
|
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
|
J Clin Oncol
|
2003
|
2.33
|
|
6
|
Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.
|
J Clin Oncol
|
2011
|
2.31
|
|
7
|
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
|
Blood
|
2003
|
2.31
|
|
8
|
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report.
|
Biol Blood Marrow Transplant
|
2006
|
2.24
|
|
9
|
Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.
|
Blood
|
2002
|
2.14
|
|
10
|
Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
11
|
Impending challenges in the hematopoietic stem cell transplantation physician workforce.
|
Biol Blood Marrow Transplant
|
2009
|
1.97
|
|
12
|
Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.
|
Blood
|
2009
|
1.96
|
|
13
|
Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation.
|
J Clin Oncol
|
2005
|
1.93
|
|
14
|
Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States.
|
Blood
|
2010
|
1.85
|
|
15
|
First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
1.74
|
|
16
|
Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made?
|
J Clin Oncol
|
2011
|
1.74
|
|
17
|
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.
|
Blood
|
2005
|
1.73
|
|
18
|
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).
|
Blood
|
2013
|
1.71
|
|
19
|
Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls.
|
J Clin Oncol
|
2007
|
1.70
|
|
20
|
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.
|
Blood
|
2009
|
1.70
|
|
21
|
Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
|
Blood
|
2006
|
1.67
|
|
22
|
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
|
Biol Blood Marrow Transplant
|
2008
|
1.67
|
|
23
|
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
|
J Clin Oncol
|
2013
|
1.66
|
|
24
|
Access to hematopoietic cell transplantation in the United States.
|
Biol Blood Marrow Transplant
|
2009
|
1.62
|
|
25
|
Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries.
|
Br J Haematol
|
2003
|
1.58
|
|
26
|
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
|
Blood
|
2002
|
1.57
|
|
27
|
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia.
|
Blood
|
2012
|
1.57
|
|
28
|
Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases.
|
J Clin Oncol
|
2002
|
1.55
|
|
29
|
Race and socioeconomic status influence outcomes of unrelated donor hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.52
|
|
30
|
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.
|
Blood
|
2013
|
1.50
|
|
31
|
Allogeneic transplant physician and center capacity in the United States.
|
Biol Blood Marrow Transplant
|
2011
|
1.49
|
|
32
|
Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
|
Biol Blood Marrow Transplant
|
2012
|
1.46
|
|
33
|
Access to hematopoietic stem cell transplantation: effect of race and sex.
|
Cancer
|
2010
|
1.43
|
|
34
|
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.
|
Blood
|
2010
|
1.38
|
|
35
|
Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada.
|
J Clin Oncol
|
2003
|
1.38
|
|
36
|
Trends in use of and survival after autologous hematopoietic cell transplantation in North America, 1995-2005: significant improvement in survival for lymphoma and myeloma during a period of increasing recipient age.
|
Biol Blood Marrow Transplant
|
2013
|
1.31
|
|
37
|
Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
|
J Clin Oncol
|
2010
|
1.24
|
|
38
|
Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management.
|
J Allergy Clin Immunol
|
2009
|
1.23
|
|
39
|
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
|
Biol Blood Marrow Transplant
|
2009
|
1.22
|
|
40
|
Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes.
|
Biol Blood Marrow Transplant
|
2011
|
1.21
|
|
41
|
Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia.
|
Chest
|
2005
|
1.21
|
|
42
|
The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls.
|
Biol Blood Marrow Transplant
|
2009
|
1.18
|
|
43
|
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.
|
Blood
|
2004
|
1.18
|
|
44
|
Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States.
|
Blood
|
2004
|
1.16
|
|
45
|
Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.
|
Biol Blood Marrow Transplant
|
2010
|
1.15
|
|
46
|
Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.14
|
|
47
|
Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
|
Biol Blood Marrow Transplant
|
2009
|
1.14
|
|
48
|
Subcutaneous plasmacytomas with tropism to sites of previous trauma in a multiple myeloma patient treated with an autologous bone marrow transplant.
|
Am J Hematol
|
2003
|
1.14
|
|
49
|
Long-term survival and late relapse in 2-year survivors of autologous haematopoietic cell transplantation for Hodgkin and non-Hodgkin lymphoma.
|
Br J Haematol
|
2009
|
1.13
|
|
50
|
Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR).
|
Biol Blood Marrow Transplant
|
2010
|
1.11
|
|
51
|
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review.
|
Biol Blood Marrow Transplant
|
2007
|
1.10
|
|
52
|
Surviving the cure: long term followup of hematopoietic cell transplant recipients.
|
Bone Marrow Transplant
|
2013
|
1.08
|
|
53
|
Optimistic expectations and survival after hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2003
|
1.08
|
|
54
|
Second unrelated donor hematopoietic cell transplantation for primary graft failure.
|
Biol Blood Marrow Transplant
|
2010
|
1.06
|
|
55
|
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.
|
Blood
|
2002
|
1.03
|
|
56
|
Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma.
|
Biol Blood Marrow Transplant
|
2009
|
1.00
|
|
57
|
Factors associated with self-reported physical and mental health after hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.96
|
|
58
|
Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2011
|
0.95
|
|
59
|
Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI.
|
Mol Genet Metab
|
2010
|
0.91
|
|
60
|
The National Marrow Donor Program's symposium on patient advocacy in cellular transplantation therapy: addressing barriers to hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.91
|
|
61
|
The effect of smoking on allogeneic transplant outcomes.
|
Biol Blood Marrow Transplant
|
2009
|
0.88
|
|
62
|
Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities.
|
Biol Blood Marrow Transplant
|
2005
|
0.88
|
|
63
|
Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.
|
Biol Blood Marrow Transplant
|
2009
|
0.86
|
|
64
|
Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.84
|
|
65
|
Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia.
|
Biol Blood Marrow Transplant
|
2010
|
0.83
|
|
66
|
Methodological and logistical considerations to study design and data collection in racial/ethnic minority populations evaluating outcome disparity in hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.83
|
|
67
|
Relationships among symptoms, psychosocial factors, and health-related quality of life in hematopoietic stem cell transplant survivors.
|
Support Care Cancer
|
2014
|
0.81
|
|
68
|
Utility of single versus tandem autotransplants for advanced testes/germ cell cancer: a center for international blood and marrow transplant research (CIBMTR) analysis.
|
Biol Blood Marrow Transplant
|
2007
|
0.81
|
|
69
|
Barriers to hematopoietic cell transplantation clinical trial participation of african american and black youth with sickle cell disease and their parents.
|
J Pediatr Hematol Oncol
|
2013
|
0.81
|
|
70
|
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
|
Biol Blood Marrow Transplant
|
2008
|
0.79
|
|
71
|
Are there circumstances in which phase 2 study results should be practice-changing?
|
Hematology Am Soc Hematol Educ Program
|
2007
|
0.79
|
|
72
|
Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation.
|
Semin Hematol
|
2012
|
0.78
|
|
73
|
[Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation].
|
Rinsho Ketsueki
|
2014
|
0.78
|
|
74
|
Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the American Society for Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
0.75
|
|
75
|
Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology.
|
Arch Pathol Lab Med
|
2017
|
0.75
|
|
76
|
The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation.
|
Biol Blood Marrow Transplant
|
2005
|
0.75
|